Vinblastine
- Atc Codes:L01CA01
- CAS Codes:143-67-9#865-21-4
- PHARMGKB ID:143-67-9#865-21-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Velbe, Vinblastin; Belgium: Vinblasin; Bulgaria: Cytoblastin; Czech Republic: Vinblastin; Denmark: Velbe; Estonia: Vinblastine; Finland: Velbe; France: Velbe; Germany: Vinblastin; Greece: Velbe, Vinblastine; Hungary: Vinblastin; Ireland: Vinblastine; Italy: Velbe; Latvia: Vinblastine; Lithuania: Vinblastin; Luxembourg: Velbe; Netherlands: Blastivin, Vinblastine; Poland: Velbe; Portugal: Solblastin, Vinblastina; Romania: Vinblastine; Slovakia: Vinblastin; Spain: Vinblastina; Sweden: Velbe; UK: Vinblastine.
North America
Canada: Vinblastine; USA: Vinblastine.
Latin America
Argentina: Vinblastina; Mexico: Lemblastine, Vinblastina.
Asia
Japan: Exal.
Drug combinations
Vinblastine, Cisplatin, and Dacarbazine
Chemistry
Vinblastine Sulfate: C~46~H~58~N~4~O~9~ H~2~SO~4~. Mw: 909.05. Vincaleukoblastine, sulfate (1:1). CAS-143-67-9; CAS-865-21-4 (vinblastine)(1962).
Pharmacologic Category
Antineoplastic Agents; Plant Alkaloids and Other Natural Products. Vinca Alkaloid. (ATC-Code: L01CA01).
Mechanism of action
Vinblastine binds to tubulin and inhibits microtubule formation, therefore arresting cell at metaphase by disrupting formation of mitotic spindle. Vinblastine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.
Therapeutic use
Treatment of Hodgkin’s and non-Hodgkin lymphoma. Testicular cancer. Breast cancer. Mycosis fungoides. Kaposi’s sarcoma. Histiocytosis (Letterer-Siwe disease). Choriocarcinoma.
Pregnancy and lactiation implications
Animal studies demonstrated resorption and teratogenic effects. There are no adequate, well-controlled studies in pregnant women. Not recommended in nursing women.
Unlabeled use
Treatment of bladder cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, soft tissue sarcoma (desmoid tumors).
Contraindications
Significant granulocytopenia. Presence of bacterial infection. I.T. administration (may result in death).
Warnings and precautions
Hazardous agent. May cause bone marrow suppression (leukopenia, granulocytopenia). Leukopenia may be more pronounced in cachectic patients and skin ulceration. Thrombocytopenia and anemia may occur rarely. May rarely cause disabling neurotoxicity. Use with caution in hepatic impairment (toxicity may be increased), and in ischemic heart disease. Itraconazole may decrease metabolism of vinblastine via CYP3A4 inhibition and may increase effects of vinblastine via P-glycoprotein effects. Severe myelosuppression and neurotoxicity may occur. Acute shortness of breath and severe bronchospasm reported, most often in association with concurrent administration of mitomycin (use caution in pre-existing pulmonary disease). Not for intrathecal use (may result in death). For I.V. use only. Vinblastine is a moderate vesicant (avoid extravasation).